HRP20110639T1 - 4-metil-n-[3-4(-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamid-monohidroklorid-monohidratna sol - Google Patents
4-metil-n-[3-4(-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamid-monohidroklorid-monohidratna sol Download PDFInfo
- Publication number
- HRP20110639T1 HRP20110639T1 HR20110639T HRP20110639T HRP20110639T1 HR P20110639 T1 HRP20110639 T1 HR P20110639T1 HR 20110639 T HR20110639 T HR 20110639T HR P20110639 T HRP20110639 T HR P20110639T HR P20110639 T1 HRP20110639 T1 HR P20110639T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- ylamino
- imidazol
- pyridin
- trifluoromethyl
- Prior art date
Links
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 title claims abstract 4
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- YCBPQSYLYYBPDW-UHFFFAOYSA-N 4-methyl-n-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide;hydrate;hydrochloride Chemical group O.Cl.C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 YCBPQSYLYYBPDW-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 238000001816 cooling Methods 0.000 claims 3
- 239000011541 reaction mixture Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 238000003756 stirring Methods 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- 238000001914 filtration Methods 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 238000010899 nucleation Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- -1 4-methyl-imidazol-1-yl Chemical group 0.000 abstract 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Sol od 4-metil-N-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida, naznačena time, da je to monohidroklorid monohidrat 4-metil-N-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida. Patent sadrži još 3 patentna zahtjeva.
Claims (4)
1. Sol od 4-metil-N-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida, naznačena time, da je to monohidroklorid monohidrat 4-metil-N-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida.
2. Postupak za pripravljanje 4-metil-N-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamid-monohidroklorid monohidrata, naznačen time, da obuhvaća sljedeće korake:
(a) povezivanje slobodne baze 4-metil-N-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida i klorovodične kiseline u metanolu pod dušikovim zračnim omotačem;
(b) zagrijavanje reakcijske smjese na temperaturi u rasponu od oko 42-50°C;
(c) miješanje reakcijske smjese;
(d) filtriranje reakcijske smjese dok se održava temperatura iznad 40°C da se dobije bistra otopina;
(e) hlađenje bistre otopine na oko 30°C dok se ona miješa pod dušikovim zračnim omotačem;
(f) zasijavanje otopine;
(g) hlađenje zasijane otopine na oko 23°C;
(h) miješanje otopine da se dobije suspenzija;
(i) hlađenje suspenzije na oko -10°C;
(j) miješanje suspenzije;
(k) filtriranje krutina;
(l) ispiranje krutina hladnim metanolom; i
(m) sušenje krutina na oko 50-55°C i 10-20 tora da se dobije 4-metil-N-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamid-monohidroklorid monohidratna sol.
3. Farmaceutski sastav, naznačen time, da obuhvaća:
(a) terapeutski učinkovitu količinu soli prema zahtjevu 1; i
(b) barem jedan(no) farmaceutski prihvatljiv(o) nosač, razrjeđivač, prijenosno sredstvo ili pomoćno sredstvo.
4. Uporaba terapeutski učinkovite količine soli prema zahtjevu 1, naznačena time, da je za proizvodnju lijeka za liječenje bolesti koja odgovara inhibiciji djelovanja proteinske kinaze.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70140605P | 2005-07-20 | 2005-07-20 | |
| US71621305P | 2005-09-12 | 2005-09-12 | |
| PCT/US2006/027878 WO2007015871A1 (en) | 2005-07-20 | 2006-07-18 | Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110639T1 true HRP20110639T1 (hr) | 2011-10-31 |
Family
ID=37398525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110639T HRP20110639T1 (hr) | 2005-07-20 | 2011-09-07 | 4-metil-n-[3-4(-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamid-monohidroklorid-monohidratna sol |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US8163904B2 (hr) |
| EP (2) | EP1910336B1 (hr) |
| JP (1) | JP5129132B2 (hr) |
| KR (3) | KR20080027855A (hr) |
| CN (1) | CN102267981A (hr) |
| AR (1) | AR057467A1 (hr) |
| AT (1) | ATE514689T1 (hr) |
| AU (2) | AU2006276205B2 (hr) |
| BR (1) | BRPI0613605A2 (hr) |
| CA (2) | CA2823946C (hr) |
| CY (1) | CY1111772T1 (hr) |
| DK (1) | DK1910336T3 (hr) |
| EC (1) | ECSP088118A (hr) |
| ES (1) | ES2634291T3 (hr) |
| GT (1) | GT200600316A (hr) |
| HK (1) | HK1116778A1 (hr) |
| HR (1) | HRP20110639T1 (hr) |
| IL (1) | IL187787A (hr) |
| JO (1) | JO2757B1 (hr) |
| MA (1) | MA29686B1 (hr) |
| MX (1) | MX2008000892A (hr) |
| MY (1) | MY149889A (hr) |
| NO (1) | NO341313B1 (hr) |
| NZ (2) | NZ564182A (hr) |
| PE (1) | PE20070241A1 (hr) |
| PL (1) | PL1910336T3 (hr) |
| PT (1) | PT1910336E (hr) |
| RU (4) | RU2434864C2 (hr) |
| SG (1) | SG170772A1 (hr) |
| SI (1) | SI1910336T1 (hr) |
| TN (1) | TNSN08028A1 (hr) |
| TW (1) | TWI455934B (hr) |
| UY (1) | UY29683A1 (hr) |
| WO (1) | WO2007015871A1 (hr) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200600315A (es) | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
| GT200600316A (es) * | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
| US20100152198A1 (en) * | 2006-04-07 | 2010-06-17 | Manley Paul W | Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia |
| EP1923053A1 (en) * | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
| WO2010009402A2 (en) | 2008-07-17 | 2010-01-21 | Teva Pharmaceutical Industries Ltd. | Nilotinib intermediates and preparation thereof |
| ES2394258T3 (es) | 2008-11-05 | 2013-01-30 | Teva Pharmaceutical Industries Ltd. | Formas cristalinas de Nilotinib HCL |
| EP2186514B1 (en) * | 2008-11-14 | 2016-06-29 | Kinki University | Treatment of Malignant Peripheral Nerve Sheath Tumors |
| EP2403492A1 (en) | 2009-03-06 | 2012-01-11 | Novartis AG | Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak) |
| TW201102068A (en) | 2009-06-02 | 2011-01-16 | Novartis Ag | Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms |
| US20110053968A1 (en) * | 2009-06-09 | 2011-03-03 | Auspex Pharmaceuticals, Inc. | Aminopyrimidine inhibitors of tyrosine kinase |
| WO2011033307A1 (en) | 2009-09-17 | 2011-03-24 | Generics [Uk] Limited | Nilotinib dihydrochloride salt |
| KR101853596B1 (ko) | 2009-10-23 | 2018-04-30 | 노파르티스 아게 | Ｂｃｒ-ａｂｌ, ｃ-ｋｉｔ, ｄｄｒ1, ｄｄｒ2 또는 ｐｄｇｆ-ｒ 키나제 활성에 의해 매개된 증식성 장애 및 다른 병적 상태의 치료 방법 |
| JO3634B1 (ar) | 2009-11-17 | 2020-08-27 | Novartis Ag | طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r |
| IN2010KO00035A (hr) | 2010-01-15 | 2016-09-02 | ||
| EP2558098A2 (en) | 2010-04-16 | 2013-02-20 | Novartis AG | Treatment of endocrine resistant breast cancer |
| EP2382976A1 (en) | 2010-04-30 | 2011-11-02 | Hiroshima University | Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer |
| PL2571863T3 (pl) | 2010-06-21 | 2016-03-31 | Teva Pharma | Sole nilotynibu i ich postacie krystaliczne |
| WO2012014127A1 (en) | 2010-07-30 | 2012-02-02 | Ranbaxy Laboratories Limited | 5-lipoxygenase inhibitors |
| CN102453024B (zh) * | 2010-10-27 | 2014-09-03 | 浙江九洲药业股份有限公司 | 一种尼罗替尼盐酸盐晶型及其制备方法 |
| IN2010CH03577A (hr) * | 2010-11-26 | 2012-07-20 | Hetero Research Foundation | |
| AR086913A1 (es) * | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas |
| WO2013063003A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
| JP2014532647A (ja) | 2011-10-28 | 2014-12-08 | ノバルティス アーゲー | 消化管間質腫瘍を治療する方法 |
| SG10201707768RA (en) | 2011-11-14 | 2017-10-30 | Novartis Ag | Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation |
| AU2013289175A1 (en) | 2012-07-11 | 2015-01-22 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
| AU2013332205B2 (en) * | 2012-10-15 | 2017-08-31 | Apotex Inc. | Solid forms of Nilotinib hydrochloride |
| EP2909191B1 (en) * | 2012-10-19 | 2019-03-20 | Basf Se | Multicomponent crystalline system comprising nilotinib and selected co-crystal formers |
| EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
| WO2014174456A2 (en) | 2013-04-24 | 2014-10-30 | Dr. Reddys Laboratories Limited | Polymorphic forms of nilotinib hydrochloride |
| RU2551359C9 (ru) * | 2013-11-28 | 2021-08-20 | Общество с ограниченной ответственностью "Мамонт Фарм" | Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе |
| WO2015092624A1 (en) | 2013-12-16 | 2015-06-25 | Ranbaxy Laboratories Limited | Nilotinib mono-oxalate and its crystalline form |
| WO2016020891A1 (en) | 2014-08-08 | 2016-02-11 | Dr. Reddy’S Laboratories Limited | Process for the preparation of polymorphic forms of nilotinib |
| PT3189045T (pt) | 2014-08-11 | 2022-03-17 | Sun Pharmaceutical Ind Ltd | Novos sais de nilotinib e polimorfos do mesmo |
| US10301282B2 (en) | 2015-03-20 | 2019-05-28 | Cipla Limited | Polymorphic form X of nilotinib dihydrochloride hydrate |
| SI3408264T1 (sl) | 2016-01-26 | 2020-07-31 | Farma Grs, D.O.O. | Nilotinibijev dinitrat (V) in njegove kristalne oblike |
| WO2017149550A1 (en) * | 2016-03-02 | 2017-09-08 | Msn Laboratories Private Limited | Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide |
| WO2017160703A1 (en) | 2016-03-14 | 2017-09-21 | Pliva Hrvatska D.O.O. | Solid state forms of nilotinib salts |
| EP3404025B1 (en) | 2017-05-16 | 2019-12-04 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Process for the preparation of pure nilotinib and its salt |
| CZ2017821A3 (cs) | 2017-12-20 | 2019-07-03 | Zentiva, K.S. | Léková forma obsahující krystalický nilotinib |
| JP7409696B2 (ja) * | 2018-06-15 | 2024-01-09 | ハンダ ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤の塩およびその組成物 |
| US20210380557A1 (en) * | 2018-11-05 | 2021-12-09 | Laurus Labs Limited | Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same |
| US10874671B2 (en) * | 2019-02-18 | 2020-12-29 | Slayback Pharma Llc | Pharmaceutical compositions of nilotinib |
| WO2021155254A1 (en) | 2020-01-31 | 2021-08-05 | Nanocopoeia, Llc | Amorphous nilotinib microparticles and uses thereof |
| US20230075170A1 (en) | 2020-02-15 | 2023-03-09 | Cipla Limited | Novel salts of nilotinib and polymorphic forms thereof |
| IL297776A (en) | 2020-04-30 | 2022-12-01 | Nanocopoeia Llc | Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib |
| CN114133378B (zh) * | 2020-09-04 | 2023-08-15 | 成都苑东生物制药股份有限公司 | 一种盐酸尼洛替尼共晶及其制备方法 |
| EP4260848A1 (en) | 2022-04-11 | 2023-10-18 | Lotus Pharmaceutical Co., Ltd. | Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2081108C1 (ru) * | 1991-10-16 | 1997-06-10 | Циба-Гейги АГ | Аддитивные соли кислот с основанием и фармацевтическая композиция, обладающая противоопухолевой активностью |
| US5516775A (en) * | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
| KR100330553B1 (ko) | 1993-10-01 | 2002-11-27 | 노파르티스 아게 | 약물학적활성피리딘유도체및그의제조방법 |
| CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| AR026936A1 (es) * | 1999-12-14 | 2003-03-05 | Nippon Shinyaku Co Ltd | Compuestos heterociclicos y composiciones que los contienen |
| GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB2398565A (en) * | 2003-02-18 | 2004-08-25 | Cipla Ltd | Imatinib preparation and salts |
| MY144177A (en) | 2004-02-04 | 2011-08-15 | Novartis Ag | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide. |
| SA06270147B1 (ar) * | 2005-06-09 | 2009-12-22 | نوفارتيس ايه جي | عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين |
| GT200600316A (es) * | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
| GT200600315A (es) | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida |
-
2006
- 2006-07-14 GT GT200600316A patent/GT200600316A/es unknown
- 2006-07-18 SG SG201102150-8A patent/SG170772A1/en unknown
- 2006-07-18 DK DK06787733.2T patent/DK1910336T3/da active
- 2006-07-18 MY MYPI20063405A patent/MY149889A/en unknown
- 2006-07-18 AR ARP060103071A patent/AR057467A1/es unknown
- 2006-07-18 NZ NZ564182A patent/NZ564182A/en unknown
- 2006-07-18 KR KR1020087001461A patent/KR20080027855A/ko not_active Application Discontinuation
- 2006-07-18 US US11/995,898 patent/US8163904B2/en active Active
- 2006-07-18 CN CN2011102503529A patent/CN102267981A/zh active Pending
- 2006-07-18 RU RU2008105827/04A patent/RU2434864C2/ru active
- 2006-07-18 BR BRPI0613605-2A patent/BRPI0613605A2/pt not_active Application Discontinuation
- 2006-07-18 MX MX2008000892A patent/MX2008000892A/es active IP Right Grant
- 2006-07-18 SI SI200631100T patent/SI1910336T1/sl unknown
- 2006-07-18 KR KR1020157022022A patent/KR101755137B1/ko active IP Right Grant
- 2006-07-18 EP EP06787733A patent/EP1910336B1/en active Active
- 2006-07-18 RU RU2012143989/04A patent/RU2509767C1/ru active
- 2006-07-18 WO PCT/US2006/027878 patent/WO2007015871A1/en active Application Filing
- 2006-07-18 NZ NZ591142A patent/NZ591142A/xx unknown
- 2006-07-18 ES ES10150322.5T patent/ES2634291T3/es active Active
- 2006-07-18 PT PT06787733T patent/PT1910336E/pt unknown
- 2006-07-18 PL PL06787733T patent/PL1910336T3/pl unknown
- 2006-07-18 AU AU2006276205A patent/AU2006276205B2/en active Active
- 2006-07-18 RU RU2011120363/04A patent/RU2483065C2/ru active
- 2006-07-18 CA CA2823946A patent/CA2823946C/en active Active
- 2006-07-18 EP EP10150322.5A patent/EP2186808B1/en active Active
- 2006-07-18 JP JP2008522900A patent/JP5129132B2/ja active Active
- 2006-07-18 CA CA2615669A patent/CA2615669C/en active Active
- 2006-07-18 AT AT06787733T patent/ATE514689T1/de active
- 2006-07-18 KR KR1020147007695A patent/KR20140047737A/ko not_active Application Discontinuation
- 2006-07-19 TW TW095126416A patent/TWI455934B/zh active
- 2006-07-20 UY UY29683A patent/UY29683A1/es not_active Application Discontinuation
- 2006-07-20 JO JO2006242A patent/JO2757B1/en active
- 2006-07-20 PE PE2006000874A patent/PE20070241A1/es active IP Right Grant
-
2007
- 2007-11-29 IL IL187787A patent/IL187787A/en active IP Right Grant
-
2008
- 2008-01-09 MA MA30563A patent/MA29686B1/fr unknown
- 2008-01-18 TN TNP2008000028A patent/TNSN08028A1/en unknown
- 2008-01-18 EC EC2008008118A patent/ECSP088118A/es unknown
- 2008-02-20 NO NO20080897A patent/NO341313B1/no unknown
- 2008-07-08 HK HK08107504.6A patent/HK1116778A1/xx unknown
-
2010
- 2010-11-12 AU AU2010241419A patent/AU2010241419C1/en active Active
-
2011
- 2011-08-26 CY CY20111100813T patent/CY1111772T1/el unknown
- 2011-09-07 HR HR20110639T patent/HRP20110639T1/hr unknown
-
2012
- 2012-03-13 US US13/419,132 patent/US8389537B2/en active Active
-
2013
- 2013-01-15 RU RU2013101749/04A patent/RU2605551C2/ru active
- 2013-01-22 US US13/747,052 patent/US8580806B2/en active Active
- 2013-10-11 US US14/051,725 patent/US9163005B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110639T1 (hr) | 4-metil-n-[3-4(-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamid-monohidroklorid-monohidratna sol | |
| EP1276738B1 (en) | 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors | |
| ES2292488T3 (es) | Derivados de la urea, como agentes antiinflamatorios. | |
| CN103965120B (zh) | 喹啉及喹唑啉衍生物、制备方法、中间体、组合物及应用 | |
| WO2017038838A1 (ja) | 新規なピラゾロ［３，４－ｄ］ピリミジン化合物又はその塩 | |
| MY141754A (en) | Selected cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions | |
| CA3036594A1 (en) | Alkynyl-substituted heterocyclic compound, preparation method thereof and medical use thereof | |
| WO2005021519A3 (en) | 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases | |
| CN101686675A (zh) | 化合物 | |
| GEP20094804B (en) | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | |
| IL169534A0 (en) | N-(1-benzyl-2-oxo-2-(1-piperazinyl) ethyl)-1-piperidincarboxamid-derivatives and related compounds use as cgrp-antagonists for headache | |
| CA2626375A1 (en) | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer | |
| TW200606151A (en) | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | |
| JP2010522186A (ja) | 化合物 | |
| JP2010515770A (ja) | ニコチン性アセチルコリン受容体モジュレーター | |
| US20100056515A1 (en) | Benzimidazole compounds | |
| DE60310767T2 (de) | PYRAZOL-3,4-d-PYRIMIDINDERIVATE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON H.PYLORI-INFEKTIONEN | |
| CA2387134A1 (en) | Cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof | |
| CN100439365C (zh) | 用作蛋白激酶抑制剂的化合物和组合物 | |
| AU2006297889A1 (en) | New compounds II | |
| JP7171057B2 (ja) | ヘテロアリール化合物およびその使用 | |
| KR20200041954A (ko) | 화합물, 이의 약제학적 조성물, 및 이의 용도 및 응용 | |
| EP3297991B1 (en) | Novel amidoheteroaryl aroyl hydrazide ethynes | |
| DE602006009556D1 (de) | Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen | |
| CN104804001B (zh) | 4‑取代吡咯并[2,3‑d]嘧啶化合物及其用途 |